Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
March 19 2024 - 7:30AM
Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a
clinical-stage TechBio company specializing in developing
AI-Immunology™ powered vaccines, today hosts a Research &
Development (R&D) Day focusing on its core AI-Immunology™
platform. The event will be hosted at our facilities in Hørsholm,
Denmark, between 14.00 – 18.00 CET / 9.00 a.m. - 1.00 p.m. EST and
can be accessed remotely here.
The R&D Day features a series of talks
providing in-depth insights into Evaxion's clinically validated
AI-Immunology™ platform for vaccine target discovery, design and
development. AI-Immunology™ consists of a collection of in-house
developed AI building blocks that can be intelligently combined
into AI prediction models to address complex healthcare issues
related to the immune system. With the AI prediction models,
PIONEER™, ObsERV™, EDEN™ and RAVEN™, we can identify clinically
relevant vaccine targets within hours.
Christian Kanstrup, CEO of Evaxion, expresses
enthusiasm: “We have been looking forward to this exciting day and
welcome everyone interested in learning more about our technology
and its potential for saving and improving lives. We believe that
we hold a truly differentiated position driven by our validated
AI-Immunology™ platform and the multi-disciplinary capability set
we have built around it. The potential of AI-Immunology™ is
evidenced by our strong pipeline of vaccine candidates and existing
partnerships.”
The presentations during the day will, among
other things, cover:
- The innovative
modular architecture of AI-Immunology™, where AI building blocks
can be combined into AI prediction models, enhancing
scalability
- Insights into the
novel AI-Immunology™ building block, EvaxMHC,
which is used across the platform, significantly enhancing the
predictive capabilities
- The clinical
validation of the predictive capabilities of the
PIONEER™ model showing a statistically significant
improvement in progression-free survival in metastatic melanoma
patients
- The novel tumor
target sources, named Endogenous Retroviruses (ERVs), showing high
relevance in low tumor mutation burden cancers, allowing for
potentially more effective personal cancer vaccines
- The
EDEN™ model outperforms reverse vaccinology
finding novel targets in hours instead of years. The EDEN™ designed
EVX-B2 vaccine candidate showing stronger protection than a vaccine
candidate developed by GSK’s Gonorrhea
-
RAVEN™ introduces novel vaccine concepts to
enhance the effectiveness of T-cell-based vaccines
- The
ObsERV™ model allows for a novel precision vaccine
approach toward addressing cancers which cannot be targeted with
standard immunotherapies
Following the R&D Day, a replay of the event presentations
will be available on our website.
About AI-Immunology™
AI-Immunology™ is a scalable and adaptable
artificial intelligence technology platform at the forefront of
vaccine discovery for infectious diseases and cancers. By
integrating the collective power of proprietary AI models PIONEER™,
EDEN™, RAVEN™, and ObsERV™, the platform can model the complexity
of the patient's immune system. AI-Immunology™ advanced
computational modelling swiftly and uniquely identifies, predicts,
and designs vaccine candidates, revolutionizing the landscape of
immunotherapy by offering a holistic and personalized approach to
combat fast-evolving pathogens and malignant cells.
About EVAXION
Evaxion Biotech A/S is a pioneering TechBio
company based upon its AI platform, AI-Immunology™. Evaxion's
proprietary and scalable AI prediction models harness the power of
artificial intelligence to decode the human immune system and
develop novel immunotherapies for cancer, bacterial diseases, and
viral infections. Based upon AI-Immunology™, Evaxion has developed
a clinical-stage oncology pipeline of novel personalized vaccines
and a preclinical infectious disease pipeline in bacterial and
viral diseases with high unmet medical needs. Evaxion is committed
to transforming patients' lives by providing innovative and
targeted treatment options. For more information about Evaxion and
its groundbreaking AI-Immunology™ platform and vaccine pipeline,
please visit our website.
Forward-Looking
Statement
This announcement contains forward-looking
statements within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended. The words "target," "believe,"
"expect," "hope," "aim," "intend," "may," "might," "anticipate,"
"contemplate," "continue," "estimate," "plan," "potential,"
"predict," "project," "will," "can have," "likely," "should,"
"would," "could," and other words and terms of similar
meaning identify forward-looking statements. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various factors,
including, but not limited to, risks related to: our financial
condition and need for additional capital; our development work;
cost and success of our product development activities and
preclinical and clinical trials; commercializing any approved
pharmaceutical product developed using our AI platform technology,
including the rate and degree of market acceptance of our product
candidates; our dependence on third parties including for conduct
of clinical testing and product manufacture; our inability to enter
into partnerships; government regulation; protection of our
intellectual property rights; employee matters and managing growth;
our ADSs and ordinary shares, the impact of international
economic, political, legal, compliance, social and business
factors, including inflation, and the effects on our business
from the worldwide ongoing COVID-19 pandemic and the ongoing
conflict in the region
surrounding Ukraine and Russia and the Middle
East; and other uncertainties affecting our business
operations and financial condition. For a further discussion
of these risks, please refer to the risk factors included in our
most recent Annual Report on Form 20-F and other
filings with the U.S. Securities and Exchange Commission
(SEC), which are available
at www.sec.gov. We do not assume any
obligation to update any forward-looking statements except as
required by law.
Contact Information
Evaxion Biotech A/S
Christian Kanstrup
Chief Executive Officer
cka@evaxion-biotech.com
Source: Evaxion Biotech
Evaxion Biotech AS (NASDAQ:EVAX)
Historical Stock Chart
From Apr 2024 to May 2024
Evaxion Biotech AS (NASDAQ:EVAX)
Historical Stock Chart
From May 2023 to May 2024